Search Within

Robin Beth Brenner

Formats
  1. Meeting Abstract (8)
  2. Journal Article (3)
Groups
  1. Center for Pancreatic Cancer Research (11)
  2. Department of Medicine (11)
  3. Gastrointestinal Oncology Service (11)
  4. Solid Tumor Oncology Division (11)
  5. Biostatistics Service (8)
  6. Epidemiology and Biostatistics (8)

More Groups

People
  1. Eileen O'Reilly (11)
  2. Kenneth Yu (11)
  3. Marinela Capanu (8)
  4. David Kelsen (7)
  5. Alice Zervoudakis (6)
  6. Maeve Lowery (6)

More People

Years
  1. 2023 (3)
  2. 2020 (2)
  3. 2018 (3)
  4. 2017 (2)
  5. 2016 (1)
Publications
  1. Journal of Clinical Oncology (8)
  2. Cancer (2)
  3. Annals of Oncology (1)
Publishers
  1. American Society of Clinical Oncology (8)
  2. Wiley Blackwell (2)
  3. Oxford University Press (1)

Results (11)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer
    Meeting Abstract

    Tuli, R.; Keane, F.; Schoenfeld, J. D.; O'Connor, C.; White, C.; Chou, J. F.; Schwartz, C.; Larsen, M.; Brenner, R.; Park, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J. F.; Schwartz, C.; Varghese, A. M.; Larsen, M.; Balogun, F.; Brenner, R.; Yu, K. H.; Diguglielmo, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC)
    Meeting Abstract

    Keane, F.; Schoenfeld, J. D.; Crowley, F.; O'Connor, C. A.; White, C.; Schwartz, C.; Brenner, R.; Larsen, M.; Park, W.; Varghese, A. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) plus /- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation
    Meeting Abstract

    O'Reilly, E. M.; Lee, J. W.; Zalupski, M.; Capanu, M.; Park, J.; Golan, T.; Tahover, E.; Lowery, M. A.; Chou, J. F.; Sahai, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation
    Journal Article

    O'Reilly, E. M.; Lee, J. W.; Zalupski, M.; Capanu, M.; Park, J.; Golan, T.; Tahover, E.; Lowery, M. A.; Chou, J. F.; Sahai, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis
    Meeting Abstract

    Yu, K. H.; Mantha, S.; Tjan, C.; Kaufmann, E. S.; Brenner, R.; Lowery, M. A.; Ku, G. Y.; Raj, N. P.; Shcherba, M.; Goldberg, Z.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy analysis
    Meeting Abstract

    Yu, K.; Mantha, S.; Tjan, C.; Kaufmann, E.; Brenner, R. B.; Lowery, M.; Ku, G.; Raj, N.; Shcherba, M.; Goldberg, Z.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma
    Journal Article

    O'Reilly, E. M.; Lee, J. W.; Lowery, M. A.; Capanu, M.; Stadler, Z. K.; Moore, M. J.; Dhani, N.; Kindler, H. L.; Estrella, H.; Maynard, H.; more...
    Cancer (2018)

    Fulltext@MSK | Save
  • Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC)
    Meeting Abstract

    Lowery, M. A.; Harding, J. J.; Yu, K. H.; Kelsen, D. P.; Bomalaski, J. S.; Glassman, D. C.; Covington, C. M.; Brenner, R.; Hollywood, E.; Barba, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma
    Journal Article

    Lowery, M. A.; Yu, K. H.; Kelsen, D. P.; Harding, J. J.; Bomalaski, J. S.; Glassman, D. C.; Covington, C. M.; Brenner, R.; Hollywood, E.; Barba, A.; more...
    Cancer (2017)

    Fulltext@MSK | Save